Zollinger‑Ellison syndrome (MEN1 association) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder caused by gastrin‑producing tumors (gastrinomas) that usually arise in the duodenum or pancreas. Excess gastrin stimulates the stomach to secrete large amounts of gastric acid, leading to severe peptic ulcer disease, diarrhea, and malabsorption. When ZES occurs as part of multiple endocrine neoplasia type 1 (MEN1), it is termed “ZES‑MEN1 association.”

Who it affects: ZES can develop at any age but is most commonly diagnosed in adults aged 30‑60 years. MEN1 is an autosomal‑dominant hereditary syndrome; about 20‑30 % of patients with MEN1 develop ZES, and roughly 40‑50 % of all ZES cases are linked to MEN1. Men and women are equally affected.

Prevalence: Isolated ZES occurs in roughly 1 per 100,000 people worldwide, whereas MEN1 affects about 1 per 30,000 individuals. Because MEN1 predisposes to several endocrine tumors, the overall burden of ZES‑MEN1 is low but clinically significant due to its aggressive ulcer disease.

Sources: Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), WHO.

Symptoms

Symptoms arise from hyperacidic gastric secretions and from the tumor itself. The following list is comprehensive; not every patient will experience all of them.

Gastro‑intestinal symptoms

• Recurrent peptic ulcers – often multiple, large, and located beyond the duodenum (e.g., jejunal ulcers). Patients may report burning epigastric pain that worsens with meals.
• Abdominal pain – crampy or gnawing pain that may radiate to the back.
• Chronic diarrhea – watery, sometimes fatty (steatorrhea) due to acid‑induced inactivation of pancreatic enzymes.
• Heartburn / gastro‑esophageal reflux disease (GERD) – from excessive acid reaching the esophagus.
• Nausea & vomiting – especially after large meals.
• Weight loss – secondary to malabsorption and poor appetite.

Systemic / MEN1‑related symptoms

• Hypercalcemia – caused by parathyroid hyperplasia (primary hyperparathyroidism), leading to fatigue, bone pain, kidney stones.
• Pituitary adenomas – may cause headache, visual field defects, or hormonal excess (e.g., prolactin, ACTH).
• Skin manifestations – facial angiofibromas, collagenomas, or lipomas, often seen in MEN1 carriers.
• Fatigue, weakness – can be multifactorial (anemia, electrolyte disturbances).

Red‑flag symptoms that suggest complications

• Sudden, severe abdominal pain (possible perforation)
• Vomiting of blood or material that looks like coffee grounds (upper GI bleed)
• Bloody or black stools (melena)
• Unexplained high fever combined with abdominal pain (possible infection of ulcer or abscess)

Causes and Risk Factors

Underlying cause

ZES is driven by gastrin‑secreting neuroendocrine tumors (NETs) called gastrinomas. In the MEN1 setting, a germline mutation in the MEN1 tumor‑suppressor gene (encoding the protein menin) predisposes individuals to develop multiple endocrine tumors, including gastrinomas.

Genetic risk

• MEN1 mutation – autosomal dominant; each child of an affected parent has a 50 % chance of inheriting the mutation.
• Family history of MEN1 manifestations (hyperparathyroidism, pituitary adenoma, pancreatic NETs).

Other risk factors

• Age – tumor penetrance increases with age; >50 % of MEN1 carriers develop gastrinomas by age 50.
• Smoking – may accelerate neuroendocrine tumor growth, although data are limited.
• Chronic gastritis – can mask early ulcer symptoms, delaying diagnosis.

Who is most at risk?

Anyone with a confirmed MEN1 mutation, especially those who have already manifested another MEN1 tumor (parathyroid or pituitary), should be considered high risk for ZES. Sporadic (non‑MEN1) gastrinomas are also possible but account for only ~50‑60 % of all gastrinomas.

Diagnosis

Diagnosing ZES‑MEN1 requires a combination of clinical suspicion, biochemical testing, imaging, and often genetic confirmation.

Biochemical tests

• Fasting serum gastrin level – markedly elevated (>1000 pg/mL) is highly suggestive; values >10 × upper‑limit with gastric pH < 2 confirm hypergastrinemia.
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin is diagnostic for gastrinoma.
• Gastric pH measurement – low pH (<2) confirms acid hypersecretion.
• For MEN1 carriers: Serum calcium & PTH to assess hyperparathyroidism; pituitary hormone panels if symptoms arise.

Imaging studies

• CT scan (multiphase abdomen) – identifies pancreatic/duodenal masses >1 cm.
• Multiphasic MRI – superior soft‑tissue contrast for small lesions.
• Endoscopic ultrasound (EUS) – detects lesions as small as 2‑3 mm and allows fine‑needle aspiration.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – highly sensitive for neuroendocrine tumors and useful for staging.

Genetic testing

Sequencing of the MEN1 gene confirms hereditary disease. Testing is recommended for:

• Patients with ZES and a family history of MEN1 tumors.
• First‑degree relatives of a known MEN1 carrier.

Diagnostic criteria for ZES‑MEN1

1. Fasting gastrin >1000 pg/mL (or >10 × ULN) plus gastric pH < 2, or positive secretin stimulation test.
2. Identification of a gastrinoma on imaging or pathology.
3. Presence of a pathogenic MEN1 mutation (or a clinical MEN1 phenotype).

References: American College of Gastroenterology (2022) guideline; NIH Genetics Home Reference.

Treatment Options

Therapy is aimed at controlling acid hypersecretion, removing or reducing tumor burden, and managing other MEN1 manifestations.

Acid‑suppressive medications

• High‑dose proton pump inhibitors (PPIs) – e.g., omeprazole 60–80 mg daily or equivalent; most effective for ulcer healing and symptom control.
• Potassium‑competitive acid blockers (P‑CABs) – e.g., vonoprazan, may be used when PPIs are insufficient.
• Long‑term use is generally safe but requires monitoring for vitamin B12 deficiency, magnesium, and calcium levels.

Surgical management

Resection is the only potential cure for localized gastrinomas.

• Enucleation of small duodenal lesions.
• Pancreaticoduodenectomy (Whipple) – for larger or multiple duodenal/ pancreatic tumors.
• In MEN1, surgery is controversial because gastrinomas are often multifocal; a tailored approach (limited resection + vigilant surveillance) is common.

Medical therapies for tumor control

• Somatostatin analogues (octreotide, lanreotide) – reduce gastrin secretion and may stabilize tumor growth.
• Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive metastatic NETs.
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE for patients with high somatostatin‑receptor expression and metastatic disease.

Management of other MEN1 tumors

• Parathyroidectomy for hyperparathyroidism.
• Surgical or medical treatment of pituitary adenomas (dopamine agonists, surgery, radiotherapy).

Lifestyle and supportive measures

• Small, frequent meals; avoid foods that trigger reflux (caffeine, alcohol, spicy foods).
• Calcium and vitamin D supplementation if long‑term PPI use.
• Regular bone density testing (risk of osteoporosis from hyperparathyroidism).

Living with Zollinger‑Ellison Syndrome (MEN1 Association)

Effective long‑term management combines medication adherence, surveillance, and lifestyle adjustments.

Daily management tips

• Take PPIs exactly as prescribed – usually 30 minutes before meals; never skip doses.
• Monitor symptoms – keep a diary of pain, diarrhea, and any new GI bleeding.
• Stay hydrated – chronic diarrhea can cause electrolyte loss; oral rehydration solutions may be helpful.
• Nutrition – high‑protein, low‑fat diet can lessen steatorrhea; consider pancreatic enzyme supplements if malabsorption persists.
• Regular follow‑up – annual endoscopy, imaging every 1‑2 years, and biochemical labs every 6‑12 months.
• Family screening – first‑degree relatives should undergo genetic counseling and testing for MEN1.

Psychosocial support

Living with a hereditary cancer syndrome can be stressful. Seek support groups, mental‑health counseling, and patient advocacy organizations such as the MEN1 Foundation.

Prevention

Because MEN1 is genetic, primary prevention is not possible, but risk reduction strategies include:

• Genetic counseling for at‑risk families – informs reproductive decisions and early surveillance.
• Early detection – regular biochemical screening (fasting gastrin, calcium, PTH) beginning in adolescence for mutation carriers.
• Healthy lifestyle – smoking cessation, moderation of alcohol, and balanced diet may slow tumor progression.

Complications

If untreated or inadequately controlled, ZES‑MEN1 can lead to serious health problems:

• Perforated peptic ulcer – emergency surgery required; risk of peritonitis.
• Upper gastrointestinal bleeding – anemia, need for transfusion.
• Severe malabsorption – weight loss, nutrient deficiencies (iron, B12, fat‑soluble vitamins).
• Gastrointestinal stricture or obstruction – due to chronic ulcer scarring.
• Metastatic gastrinoma – liver or lymph node spread; poorer prognosis.
• Bone disease – from combined effects of hyperparathyroidism and chronic PPI use.
• Neuroendocrine tumor syndrome – hormonal excess from other MEN1 tumors.

When to Seek Emergency Care

---

Prepared by: Medical Content Team – based on current guidelines from the Mayo Clinic, CDC, NIH, WHO, and peer‑reviewed literature (2022‑2024). This information is for educational purposes and does not replace professional medical advice.

```